Key

Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of any advanced/metastatic cancer
suitable for treatment with capecitabine. Pancreatic cancer is not allowed and
patients with gastric or gastroesophageal junction (GEJ) cancer are only eligible if
prior treatment did not include a total gastrectomy.

- Target lesions may be in a previously irradiated field only if progression of the
lesion has been clearly documented.

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.

- Must be able to take and retain oral medications.

- Additional criteria exist.

Key Exclusion Criteria:

- Active concomitant malignancies.

- Uncontrolled or symptomatic brain metastases (if a patient has brain metastases and
is on steroids, the steroid dose must be stable for at least 30 days).

- Known dihydropyrimidine dehydrogenase (DPD) deficiency.

- Requiring intravenous (IV) alimentation.

- Known positive serology for the human immunodeficiency virus (HIV), hepatitis B
and/or hepatitis C.

- Pregnancy or lactation.

- Chemotherapy, anticancer immunotherapy, monoclonal antibodies or biologics within 21
days prior to first dose of study drug.

- Anti-EGFR and/or ErbB2 small molecule targeted therapy or hormonal anticancer therapy
within 14 days prior to first dose of study drug.

- History of any hypersensitivity to or intolerance of capecitabine or any of its
components, or to fluorouracil or any fluoropyrimidine therapy.

- Additional criteria exist.